Updated Jul 16, 2026
Ogden Christopher has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $129K.
Christopher Ogden is the Chief Financial Officer of CytomX Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. He has been involved in financial management within the biotech sector, contributing to the company's strategic financial planning.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-17 | CTMX | CytomX Therapeutics, Inc. | S — Open-market sale | 1.6K | $3.05 | $5K |
| 2026-03-19 | CTMX | CytomX Therapeutics, Inc. | S — Open-market sale | 19.3K | $6.42 | $124K |
| 2026-02-04 | CTMX | CytomX Therapeutics, Inc. | A — Grant or award | 90.0K | $0.00 |
Christopher Ogden is the Chief Financial Officer of CytomX Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. He has been involved in financial management within the biotech sector, contributing to the company's strategic financial planning.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($129K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Ogden Christopher profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.